Advertisement

Synthesis and Pharmacological Properties of 1-(6-Aminohexylamino)-1-Phenylcyclohexyl Dihydrochloride (IEM-2062) as Compared with Memantine

  • V. E. GmiroEmail author
  • S. E. Serdyuk
  • O. S. Veselkina
Article
  • 1 Downloads

1-(6-Aminohexylamino)-1-phenylcyclohexyl dihydrochloride (IEM-2062) had significantly greater antihypoxic, anticonvulsant, antidepressant, and analgesic activity than memantine and similar antiparkinsonism activity as memantine; it had low toxicity and was safer for use. IEM-2062 produced significant pharmacological effects in the dose range 0.3 – 3 mg/kg.

Keywords

memantine IEM-2062 parkinsonism convulsions analgesia 

References

  1. 1.
    S. I. Gavrilova, Psikhiatriya Psikhofarmakoter., 7(2), 72 – 76 (2005).Google Scholar
  2. 2.
    O. S. Levin and L. A. Batukaeva, Zh. Nevrol. Psikhiat. im. S. S. Korsakova, 108(12), 16 – 23 (2008).Google Scholar
  3. 3.
    G. Rammes, W. Danysz, and C. G. Parsons, Curr. Neuropharmacol., 6(1), 55 – 78 (2008).CrossRefGoogle Scholar
  4. 4.
    W. Danysz, C. G. Parsons, J. Kornhuber, et al., Neurosci. Biobehav. Rev., 21(4), 455 – 468 (1997).CrossRefGoogle Scholar
  5. 5.
    C. G. Parsons, W. Danysz, and G. Quack, Neuropharmacol., 38(6), 735 – 767 (1999).CrossRefGoogle Scholar
  6. 6.
    K. K. Jain, Expert. Opin. Investig. Drugs, 9(6), 1397 – 1406 (2000).CrossRefGoogle Scholar
  7. 7.
    G. C. Palmer, Curr. Drug Targets, 2(3), 241 – 271 (2001).CrossRefGoogle Scholar
  8. 8.
    M. Rogers, A. Rasheed, A. Moradimeh, and S. J. Baumrucker, Am. J. Hosp. Palliat. Care, 26(1), 57 – 59. Review (2009).CrossRefGoogle Scholar
  9. 9.
    K. Zdanys and R. R. Tampi, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32(6), 1362 – 1374, Review (2008).CrossRefGoogle Scholar
  10. 10.
    G. Rammes, W. Danysz, and C. G. Parsons, Curr. Neuropharmacol., 6(1), 55 – 78 (2008).CrossRefGoogle Scholar
  11. 11.
    C. Ikonomidou and V. Stefovska, Proc. Natl. Acad. Sci. USA, 97(23), 12885 – 12890 (2000).CrossRefGoogle Scholar
  12. 12.
    V. E. Gmiro and S. E. Serdyuk, Éksperim. Klin. Farmakol., 63(6), 3 – 8 (2000).Google Scholar
  13. 13.
    C. G. Parsons, G. Quack, I. Bresink, et al., Neuropharmacology, 34(10), 1239 – 1258 (1995).CrossRefGoogle Scholar
  14. 14.
    V. E. Gmiro, S. E. Serdyuk, O. S. Veselkina, Byul. Éksperim. Biol. Med., 160(7), 80 – 83 (2015).Google Scholar
  15. 15.
    I. M. Fedorova, V. E. Gmiro, L. G. Magazanik, and D. B. Tikhonov, Zh. Évol. Biokhim. Fiziol., 44(6), 556 – 562 (2008).Google Scholar
  16. 16.
    M. Makosza and B. Serafin, Przem. Chem., 46(7), 393 – 394 (1967).Google Scholar
  17. 17.
    V. H. Maddox, E. F. Godefroi, and R. F. Parcell, J. Med. Chem., 8(2), 230 – 235 (1965).CrossRefGoogle Scholar
  18. 18.
    Lancaster, Chemist’s Catalogue (2000 – 2001, p. 276.Google Scholar
  19. 19.
    I. A. Revel’skii, E. N. Kapinus, M. V. Fedoseeva, et al., Zh. Anal. Khimii, 64(9), 949 – 953 (2009).Google Scholar
  20. 20.
    Guidelines for Preclinical Studies of Drugs [in Russian], A. N. Mironov (ed.), Grif i K, Moscow (2012), part 1.Google Scholar
  21. 21.
    V. E. Gmiro and S. E. Serdyuk, Éksperim. Klin. Farmakol., 63(6), 3 – 8 (2000).Google Scholar
  22. 22.
    S. E. Krahl, S. S. Senanayake, and A. Handforth, Epilepsy Res., 38(2 – 3), 171 – 175 (2000).CrossRefGoogle Scholar
  23. 23.
    A. Campbell, R. J. Baldessarini, and M. C. Cremens, Neuropharmacology, 27(11), 1197 – 1199 (1988).CrossRefGoogle Scholar
  24. 24.
    V. E. Gmiro and S. E. Serdyuk, Byul. Éksperim. Biol. Med., 143(5), 554 – 556 (2007).Google Scholar
  25. 25.
    S. E. Serdyuk and V. E. Gmiro, Byul. Éksperim. Biol. Med., 144(11), 535 – 537 (2007).Google Scholar
  26. 26.
    C. J. Woolf, G. D. Barrett, D. Mitchell, and R. A. Myers, Eur. J. Pharmacol., 45(3), 311 – 314 (1977).CrossRefGoogle Scholar
  27. 27.
    R. D. Porsolt, G. Anton, N. Blavet, and M. Jalfre, Eur. J. Pharmacol., 47(4), 379 – 391 (1978).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • V. E. Gmiro
    • 1
    Email author
  • S. E. Serdyuk
    • 1
  • O. S. Veselkina
    • 2
  1. 1.Institute of Experimental MedicineSt. PetersburgRussia
  2. 2.ZAO Vertex Pharmaceutical CompanySt. PetersburgRussia

Personalised recommendations